Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash Extracts Biomaterials Growth To Curb Reliance On Angio-Seal

This article was originally published in The Gray Sheet

Executive Summary

Kensey Nash likely will pursue an acquisition strategy and an expanded client base to leverage its biomaterial patents and manufacturing capability

You may also be interested in...



Kensey Nash Touts Prospects For TriActiv Embolic Protection Device

Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation

Kensey Nash Touts Prospects For TriActiv Embolic Protection Device

Kensey Nash believes the embolic protection market for saphenous vein graft procedures will double to more than $200 mil. in the next few years as physicians use distal protection to diminish their exposure to litigation

Distal protection device submission

Kensey Nash projects a July 510(k) submission for its TriActiv saphenous vein graft surgery distal protection device. The firm expects clearance this year, but no longer anticipates launching the system by the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. in September, as Kensey Nash previously stated in January. Former estimates were based on the assumption that a 510(k) based on the 894-patient PRIDE trial would be filed in April (1"The Gray Sheet" Jan. 26, 2004, p. 5)...

Related Content

UsernamePublicRestriction

Register

MT019648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel